Name: The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood (Video) | JoVE Journal
Uploaded: 2025-02-07T14:20:00.000+00:00
Duration: 7 min 17 s
Description: Learn to isolate low-density and normal-density neutrophils from human blood using density gradient centrifugation and magnetic separation. This protocol achieves high purity for studying neutrophil heterogeneity in health and disease.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was funded by the Health Research Board EIA-2024-002 and the Royal City of Dublin Hospital Trust. We would like to thank Dr. Lorraine Thong and Dr. Kevin Brown for their assistance in collecting samples from healthy donors for this manuscript.

Blood samples were collected with informed consent from healthy participants. The study received approval from the Research Ethics Committee of both St. James&#39;s Hospital and Tallaght University Hospital.
1. Preparation of density gradient medium, isotonic working solutions fractions and cell separation buffer
<ol>
	<li>Preparation of isotonic working solutions from density gradient medium
	<ol>
		<li>Preparation of Isotonic 100% working solution (~1.123 g/mL)
		<ol>
			<li>To prepare the isotonic 100% working solution, combine 27 mL of density gradient medium with 3 mL of 10x PBS. This results in an isotonic solution suitable for further dilutions.</li>
		</ol>
		</li>
		<li>Preparation of isotonic 81% working solution (~1.0996 g/mL)
		<ol>
			<li>Prepare the isotonic 81% working solution by mixing 8.1 mL of the isotonic 100% working solution (prepared in step 1.1.1) with 1.9 mL of 1x PBS. Mix thoroughly to ensure homogeneity.</li>
		</ol>
		</li>
		<li>Preparation of isotonic 70% working solution (~1.0861 g/mL)
		<ol>
			<li>To prepare the isotonic 70% working solution, combine 7 mL of the isotonic 100% working solution with 3 mL of 1x PBS. Ensure that the solution is well mixed.</li>
		</ol>
		</li>
		<li>Preparation of isotonic 55% working solution (1.0676 g/mL)
		<ol>
			<li>Make the isotonic 55% working solution by mixing 5.5 mL of the isotonic 100% working solution with 4.5 mL of 1x PBS. Mix thoroughly.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Layering of gradient fractions
	<ol>
		<li>Gradient fraction layering
		<ol>
			<li>Using a 15 mL conical tube, carefully layer 3 mL of the isotonic 81% working solution at the bottom. Then, slowly and gently layer 3 mL of the isotonic 70% working solution on top, avoiding mixing the layers. This gradient will be used for cell separation.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Preparation of cell separation buffer
	<ol>
		<li>Preparation of 500 mL of cell separation buffer
		<ol>
			<li>To prepare the cell separation buffer, combine 2% fetal bovine serum (FBS) and 1 mM ethylenediaminetetraacetic acid(EDTA) with 1x PBS to a total volume of 500 mL. Use this buffer to wash and resuspend cells during the isolation process. 
			NOTE: Ensure that the layers are well-separated and undisturbed. In this protocol, the isotonic working solutions are referred to as &#34;100%&#34;, &#34;81%&#34;, &#34;70%&#34;, and &#34;55%&#34; based on the method of preparation, consistent with previous studies5. However, it is important to clarify that these labels do not represent the actual final concentrations of the working solutions. For example, the &#34;100%&#34; density gradient medium is prepared by mixing 27 mL of pure density gradient medium with 3 mL of 10x PBS, resulting in a final concentration of 90% Isotonic working solution. The subsequent dilutions (e.g., &#34;81%&#34;, &#34;70%&#34;, and &#34;55%&#34;) similarly reflect preparation ratios rather than true percentage concentrations. This nomenclature was retained to maintain consistency with the terminology used in earlier literature on the subject.</li>
		</ol>
		</li>
	</ol>
	</li>
</ol>
2. Isolation of neutrophils from whole blood using negative selection
<ol>
	<li>Preparation of magnetic beads
	<ol>
		<li>Vortex the magnetic beads thoroughly for 30 s to ensure they are fully resuspended before use.</li>
	</ol>
	</li>
	<li>Blood preparation
	<ol>
		<li>For each donor, aliquot 4 mL of whole blood into three separate 14 mL round-bottomed tubes.</li>
	</ol>
	</li>
	<li>Addition of neutrophil isolation cocktail and magnetic beads
	<ol>
		<li>Add 50 &#181;L of neutrophil isolation cocktail and 50 &#181;L of magnetic beads per mL of blood to each tube. For 4 mL of blood, add 200 &#181;L of each reagent.</li>
		<li>Resuspend the mixture well by gently pipetting and incubate at room temperature (RT) for 5 min to allow the reagents to bind to unwanted cells.</li>
	</ol>
	</li>
	<li>Washing and magnetic separation - first round
	<ol>
		<li>Top up each tube to 12 mL using cell separation buffer and mix thoroughly.</li>
		<li>Place the tubes without lids on a magnet and let them incubate at RT for 10 min to allow the magnetic beads bound to unwanted cells to be drawn to the tube wall.</li>
	</ol>
	</li>
	<li>Collection of unbound cells
	<ol>
		<li>Carefully transfer the clear cell suspension containing neutrophils from each tube into a new, clean tube using a transfer pipette. Remove the original tube from the magnet.</li>
	</ol>
	</li>
	<li>Magnetic bead reapplication and incubation - second round
	<ol>
		<li>Vortex the magnetic beads again for 30 s. Add the same volume of magnetic beads to the newly transferred cell suspension as in step 2.3. Resuspend thoroughly and incubate at RT for another 5 min.</li>
	</ol>
	</li>
	<li>Final magnetic separation and collection
	<ol>
		<li>Place the tubes back onto the magnet without lids and incubate at RT for another 10 min.</li>
		<li>Carefully transfer the clear cell suspension to a new tube. This final suspension represents the isolated total neutrophil population.</li>
	</ol>
	</li>
</ol>
3. Separation of low-density neutrophils (LDNs) and normal-density neutrophils (NDNs) from the total neutrophil population
<ol>
	<li>Pooling and preparation of cell suspensions
	<ol>
		<li>For each donor, pool the isolated neutrophil suspensions into 50 mL tubes. Top up each tube to a total volume of 50 mL using the cell separation buffer.</li>
	</ol>
	</li>
	<li>Centrifugation
	<ol>
		<li>Centrifuge the tubes at 400&#160;x g for 5 min at RT with the brake on.</li>
	</ol>
	</li>
	<li>Resuspension and cell counting
	<ol>
		<li>Discard the supernatant and resuspend the neutrophil pellet in 1 mL of cell separation buffer. Perform a cell count to determine the total number of neutrophils.</li>
	</ol>
	</li>
	<li>Density gradient medium preparation
	<ol>
		<li>Centrifuge the tubes again at 400 x g for 5 min at RT with the brake on. Discard the supernatant and resuspend the neutrophil pellet in 3 mL of the 55% density gradient medium. For optimal resolution, use 3 mL of 55% density gradient medium per 5-6&#160;&#215; 106 total neutrophils.</li>
		<li>If necessary, divide the resuspended cells across multiple pre-made density gradient tubes, ensuring that 3 mL of the cell suspension is layered into each tube.</li>
	</ol>
	</li>
	<li>Layering onto density gradient tubes
	<ol>
		<li>Slowly layer the 3 mL cell suspension containing the 55% density gradient medium onto the pre-made density gradient tubes (prepared as described in section 1). Ensure careful layering to avoid disturbing the gradient.</li>
	</ol>
	</li>
	<li>Density gradient centrifugation
	<ol>
		<li>Centrifuge the tubes at 720 x g for 30 min without using the brake. After centrifugation, handle the tubes carefully to avoid disturbing the layers.</li>
	</ol>
	</li>
	<li>Isolation of neutrophil fractions
	<ol>
		<li>Following centrifugation, observe the neutrophils separate into two distinct layers: 
		Low-density neutrophils (LDNs) will be located at the 55%/70% interface, forming an upper band at approximately the 3 mL mark, and normal-density neutrophils (NDNs) will be at the 70%/81% interface, appearing as a lower band around the 6 mL mark.</li>
		<li>Using a transfer pipette, carefully isolate each layer and transfer them to separate 15 mL tubes.</li>
	</ol>
	</li>
	<li>Washing of isolated fractions
	<ol>
		<li>To wash off any residual density gradient medium, add 1x PBS to each 15 mL tube up to the 15 mL mark.</li>
		<li>Centrifuge at 400&#160;&#215; g for 5 min at RT with the brake on. If the cells do not form a firm pellet and instead remain suspended, repeat this wash step, indicating the presence of remaining density gradient medium.</li>
	</ol>
	</li>
	<li>Cell count and downstream applications
	<ol>
		<li>Count the cells in each fraction and proceed with downstream applications such as metabolic experiments, flow cytometry staining, RNA extraction, or protein lysis as needed. 
		NOTE: After plating cells out, spinning down the plate at 210&#160;&#215;&#160;g for 1 min (brake off) is recommended.</li>
	</ol>
	</li>
</ol>
4. Phenotyping of isolated LDN and NDN
<ol>
	<li>Isolate ~0.5-1&#160;&#215; 106 LDNs and NDNs. Make a 2x concentrated antibody mastermix using CD14, CD86, CD15, CD16, CD10, Fc block, and viability stain.</li>
	<li>Stain the isolated LDN and NDN populations with an equivalent volume of the antibody mastermix so that the final dilution of antibodies staining the cells is 1:100 (CD14, CD86, CD15, CD16, CD10, Fc block) and 1:50 (viability stain), respectively.</li>
	<li>Incubate the cells for 10 min in the dark at RT. 
	NOTE: Ensure the cells are thoroughly mixed with the antibody mastermix and Fc block.</li>
	<li>Wash the cells once with PBS, then centrifuge at 400&#160;&#215; g for 5 min. Discard the supernatant.</li>
	<li>Fix the cells in 1% paraformaldehyde (PFA) for 15 min at RT in the dark.</li>
	<li>Wash the cells again with PBS, centrifuge at 400&#160;&#215; g for 5 min, and discard the supernatant.</li>
	<li>Resuspend the cells in 200 &#181;L of PBS or as required to be used and acquire the cells on a flow cytometer as soon as possible. 
	NOTE: The stained and fixed cells can be stored short-term at 4 &#9702;C in the dark to prevent photobleaching the fluorophores. However, ideally, the phenotyping procedure should be carried out promptly after staining and fixation to ensure optimal cell viability and accurate results.</li>
</ol>

<ol><li>Tracchi, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Increased+neutrophil+lifespan+in+patients+with+congestive+heart+failure%5BTitle%5D)+AND+%22Eur+J+Heart+Fail%22%5BJournal%5D)">Increased neutrophil lifespan in patients with congestive heart failure.</a> Eur J Heart Fail. 11 (4), 378-385 (2009).</li>
<li>Ballesteros, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Co-option+of+neutrophil+fates+by+tissue+environments%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Co-option of neutrophil fates by tissue environments.</a> Cell. 183 (5), 1282-1297.e18 (2020).</li>
<li>Mckenna, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neutrophils%3A+Need+for+standardized+nomenclature%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Neutrophils: Need for standardized nomenclature.</a> Front Immunol. 12, 602963(2021).</li>
<li>Hacbarth, E., Kajdacsy-Balla, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Low+density+neutrophils+in+patients+with+systemic+lupus+erythematosus%2C+rheumatoid+arthritis%2C+and+acute+rheumatic+fever%5BTitle%5D)+AND+%22Arthritis+Rheumatol%22%5BJournal%5D)">Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever.</a> Arthritis Rheumatol. 29 (11), 1334-1342 (1986).</li>
<li>Hardisty, G. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High+purity+isolation+of+low+density+neutrophils+casts+doubt+on+their+exceptionality+in+health+and+disease%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">High purity isolation of low density neutrophils casts doubt on their exceptionality in health and disease.</a> Front Immunol. 12, 625922(2021).</li>
<li>Scapini, P., Marini, O., Tecchio, C., Cassatella, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+neutrophils+in+the+saga+of+cellular+heterogeneity%3A+Insights+and+open+questions%5BTitle%5D)+AND+%22Immunol+Rev%22%5BJournal%5D)">Human neutrophils in the saga of cellular heterogeneity: Insights and open questions.</a> Immunol Rev. 273 (1), 48-60 (2016).</li>
<li>Ssemaganda, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Characterization+of+neutrophil+subsets+in+healthy+human+pregnancies%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Characterization of neutrophil subsets in healthy human pregnancies.</a> PLoS One. 9 (2), e85696(2014).</li>
<li>Tay, S. H., Celhar, T., Fairhurst, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Low-density+neutrophils+in+systemic+lupus+erythematosus%5BTitle%5D)+AND+%22Arthritis+Rheumatol%22%5BJournal%5D)">Low-density neutrophils in systemic lupus erythematosus.</a> Arthritis Rheumatol. 72 (10), 1587-1595 (2020).</li>
<li>Hassani, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((On+the+origin+of+low-density+neutrophils%5BTitle%5D)+AND+%22J+Leukoc+Biol%22%5BJournal%5D)">On the origin of low-density neutrophils.</a> J Leukoc Biol. 107 (5), 809-818 (2020).</li>
<li>Cowland, J. B., Borregaard, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolation+of+neutrophil+precursors+from+bone+marrow+for+biochemical+and+transcriptional+analysis%5BTitle%5D)+AND+%22J+Immunol+Methods%22%5BJournal%5D)">Isolation of neutrophil precursors from bone marrow for biochemical and transcriptional analysis.</a> J Immunol Methods. 232 (1-2), 191-200 (1999).</li>
<li>Blanco-Camarillo, C., Aleman, O. R., Rosales, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Low-density+neutrophils+in+healthy+individuals+display+a+mature+primed+phenotype%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Low-density neutrophils in healthy individuals display a mature primed phenotype.</a> Front Immunol. 12, 672520(2021).</li>
<li>Park, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Low-density+granulocytes+display+immature+cells+with+enhanced+NET+formation+in+people+living+with+HIV%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Low-density granulocytes display immature cells with enhanced NET formation in people living with HIV.</a> Sci Rep. 13 (1), 13282(2023).</li>
<li>Denny, M. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+distinct+subset+of+proinflammatory+neutrophils+isolated+from+patients+with+systemic+lupus+erythematosus+induces+vascular+damage+and+synthesizes+type+I+IFNs%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs.</a> J Immunol. 184 (6), 3284-3297 (2010).</li>
<li>Ui Mhaonaigh, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Low+density+granulocytes+in+anca+vasculitis+are+heterogenous+and+hypo-responsive+to+anti-myeloperoxidase+antibodies%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Low density granulocytes in anca vasculitis are heterogenous and hypo-responsive to anti-myeloperoxidase antibodies.</a> Front Immunol. 10, 2603(2019).</li>
<li>Mosca, T., Forte, W. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Comparative+efficiency+and+impact+on+the+activity+of+blood+neutrophils+isolated+by+Percoll%2C+Ficoll+and+spontaneous+sedimentation+methods%5BTitle%5D)+AND+%22Immunol+Invest%22%5BJournal%5D)">Comparative efficiency and impact on the activity of blood neutrophils isolated by Percoll, Ficoll and spontaneous sedimentation methods.</a> Immunol Invest. 45 (1), 29-37 (2016).</li>
<li>Ren, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Increased+apoptotic+neutrophils+and+macrophages+and+impaired+macrophage+phagocytic+clearance+of+apoptotic+neutrophils+in+systemic+lupus+erythematosus%5BTitle%5D)+AND+%22Arthritis+Rheum%22%5BJournal%5D)">Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus.</a> Arthritis Rheum. 48 (10), 2888-2897 (2003).</li>
<li>Connelly, A. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimization+of+methods+for+the+accurate+characterization+of+whole+blood+neutrophils%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Optimization of methods for the accurate characterization of whole blood neutrophils.</a> Sci Rep. 12 (1), 3667(2022).</li>
<li>Carmona-Rivera, C., Kaplan, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Low-density+granulocytes+in+systemic+autoimmunity+and+autoinflammation%5BTitle%5D)+AND+%22Immunol+Rev%22%5BJournal%5D)">Low-density granulocytes in systemic autoimmunity and autoinflammation.</a> Immunol Rev. 314 (1), 313-325 (2023).</li>
<li>Yennemadi, A. S., Keane, J., Leisching, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mitochondrial+bioenergetic+changes+in+systemic+lupus+erythematosus+immune+cell+subsets%3A+Contributions+to+pathogenesis+and+clinical+applications%5BTitle%5D)+AND+%22Lupus%22%5BJournal%5D)">Mitochondrial bioenergetic changes in systemic lupus erythematosus immune cell subsets: Contributions to pathogenesis and clinical applications.</a> Lupus. 32 (5), 603-611 (2023).</li>
<li>Futoh, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Peripheral+low-density+granulocytes+after+colorectal+cancer+surgery+in+predicting+recurrence%5BTitle%5D)+AND+%22BJS+Open%22%5BJournal%5D)">Peripheral low-density granulocytes after colorectal cancer surgery in predicting recurrence.</a> BJS Open. 7 (1), zrac154(2023).</li>
<li>Dwivedi, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Emergence+of+dysfunctional+neutrophils+with+a+defect+in+arginase-1+release+in+severe+COVID-19%5BTitle%5D)+AND+%22JCI+Insight%22%5BJournal%5D)">Emergence of dysfunctional neutrophils with a defect in arginase-1 release in severe COVID-19.</a> JCI Insight. 9 (17), e171659(2024).</li>
</ol>

The authors have no disclosures.

Here, we present an optimized method of splitting the total neutrophil population into low- density and normal-density neutrophils, together with phenotypic characterization of each cell type using flow cytometry adapted from previous methods5.
This protocol is based on the isolation of LDNs and NDNs from whole blood. A crucial step is that total neutrophils are isolated through negative selection methods. Positive selection methods involve the use of antibodies that bi...

Neutrophils are granular immune cells and the most abundant leukocyte in peripheral blood, constituting about 50%-70% of leukocytes on average. They develop in the bone marrow from granulocyte-monocyte precursors (GMPs), which in turn develop from hematopoietic progenitor cells (HPCs) in the presence of granulocyte colony-stimulating factor (G-CSF). At homeostasis, they have a lifespan of ~24 h, but studies have shown that their lifespan can be extended under specific physiological conditions and their associated microenvironments such as chronic immune activation1, inflammation1, and even tissue residency in steady state2. Neutrophils have long been considered the first line of defense against pathogens and elicit their anti-microbial effects through 3 major effector functions -- degranulation, phagocytosis, and neutrophil extracellular trap (NET) activation and release (NETosis).
Most studies on neutrophil function and biology examine outcomes for the total neutrophil population. However, from studies in cancer settings delineating N1 (anti-tumor)/ N2 (pro-tumor) subtypes to the classification of neutrophils based on maturity, disease, and physiological state, and even cellular density (low density and normal density neutrophils), it has become increasingly apparent that the human neutrophil population constitutes phenotypically diverse subtypes. Whether the existence of these neutrophil subtypes can be attributed to being completely distinct cell types or due to the complex nature of plasticity, there exists a growing body of literature on atypical neutrophils and presents a compelling opportunity to study low-density neutrophils separate from normal-density neutrophils3.
Described for the first time in SLE patients as a pro-inflammatory neutrophil subset4, LDNs have since been identified in chronic diseases, pregnancy, and even in healthy circulation, in pro-inflammatory as well as suppressive capacities5,6,7,8. LDNs are found concurrently with peripheral blood mononuclear cells (PBMCs) when whole blood is centrifuged over density gradient media. Their specific density corresponds to approximately 1.077 g/mL, compared to NDNs at 1.083 g/mL9. While there is still considerable debate on the subject, there exists speculation that LDNs resemble a more immature granulocyte phenotype (similar to promyelocytes and myelocytes, with a density below 1.080 g/mL)9,10. Others still speculate that there are both mature and immature LDN phenotypes depending on the presence or absence of disease11,12,13. Nevertheless, LDNs have also been detected in healthy individuals; however, their inclusion in some studies is limited due to the difficulty in isolating them in sufficient numbers5.
This study aimed to isolate these two populations in quantities that would allow us to perform downstream in situ metabolic experiments (minimum 0.5&#160;&#215; 106 cells/mL). In doing so, an existing protocol5 was optimized with commonly reported phenotypic markers13,14 that provide the best outcome for isolating and characterizing LDNs and NDNs from whole blood (Figure 1A).

<table><tbody><tr><td>14 mL Polypropylene Round-Bottom Tube (17 x 100 mm)</td><td>Corning Science</td><td>352059</td><td></td></tr><tr><td>APC anti-human CD14 (63D3)</td><td>BioLegend</td><td>367118</td><td></td></tr><tr><td>Brilliant Violet 421 anti-human CD10 (25 tests)</td><td>BioLegend</td><td>312217</td><td></td></tr><tr><td>Dulbecco&#039;s Phosphate-Buffered Saline</td><td>Sigma</td><td>D8537-1L</td><td></td></tr><tr><td>EasyEights EasySep Magnet</td><td>StemCell Technologies</td><td>#18103</td><td></td></tr><tr><td>EasySep Buffer (cell separation buffer)</td><td>StemCell Technologies</td><td>#20144</td><td></td></tr><tr><td>EasySep Direct Human Neutrophil Isolation Kit</td><td>StemCell Technologies</td><td>#19666</td><td></td></tr><tr><td>FcR Blocking Reagent, human</td><td>Miltenyi Biotec</td><td>130-059-901</td><td></td></tr><tr><td>FITC anti-human CD16 (3G8)</td><td>BioLegend</td><td>302005</td><td></td></tr><tr><td>OneComp eBeads Compensation Beads</td><td>eBioscience Inc.</td><td>01-1111-42</td><td></td></tr><tr><td>PE/Cy7 anti-human CD86 (BU63)</td><td>BioLegend</td><td>374209</td><td></td></tr><tr><td>PE/Dazzle 594 anti-human CD15 (SSEA-1)</td><td>BioLegend</td><td>323037</td><td></td></tr><tr><td>Phosphate-Buffered Saline Tablets&amp;nbsp;</td><td>Gibco</td><td>18912-014</td><td></td></tr><tr><td>Zombie NIR Fixable Viability Kit</td><td>BioLegend</td><td>423105</td><td></td></tr></tbody></table>

the isolation and characterization of low- and normal- density neutrophils from whole blood

The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood

Emerging research shows that the circulating neutrophil population in humans consists of diverse subtypes and should not be studied as a single population, as has been done historically. In particular, low-density and normal-density neutrophils (LDNs, NDNs) have been shown to have functionally and metabolically distinct profiles, a factor that must be considered when publishing neutrophil research. Here, we present a modified method for the untouched isolation and separation of LDNs and NDNs from whole blood.
The density gradient medium (1.135 g/mL) is combined at 9:10 with 10x PBS. Specific density gradients of 55%, 70%, and 81% are subsequently made by combining the 100% density gradient medium with 1x phosphate-buffered saline (PBS). Neutrophils isolated from 12 mL of peripheral whole blood obtained from consented donors using a negative selection-based magnetic isolation kit are resuspended in the 55% fraction. A volume of 3 mL of the 81% and 70% fractions is layered into a 15 mL tube, followed by the 55% fraction containing total neutrophils. The density gradients are then centrifuged at 720 x&#160;g for 30 min. Two distinct bands are obtained at the 55%/70% interface (LDNs) and 70%/81% interface (NDNs). The cells are carefully pipetted into separate tubes and washed using PBS. The purity of the isolated fractions is determined using flow cytometry. Both LDNs and NDNs were defined as CD14lo CD15+ SSChi by flow cytometry. Isolation purity was calculated at &#8805;93% of viable cells for both types.
This method provides a reliable and efficient approach for separating LDN and NDNs from peripheral blood, ensuring high purity and viability of the isolated cells. Enhancing the precision of neutrophil isolation facilitates more accurate downstream analyses of these distinct neutrophil subpopulations. These are critical for advancing our understanding of neutrophil heterogeneity and its implications in various physiological and pathological contexts.

The successful layering of total neutrophils over the density gradient medium can be observed in Figure 1B. Two distinct bands should be obtained. If mixing of the gradients occurs, or the number of total neutrophils layered per tube is high (greater than roughly 5-6 × 106), the bands will look diffuse (Figure 1C), and the risk of the two neutrophil subtypes mixing increases significantly. To avoid the latter, we recommend layering up to 5-6 × 10...

Here, we provide a reliable approach for isolating low- and normal-density neutrophils from whole blood using magnetic isolation (negative selection) and discontinuous density gradient medium. It ensures untouched isolation of high-purity cells (&#8805;93%), facilitating accurate downstream analysis of neutrophil subpopulations, crucial for understanding their roles in health and disease.

Emerging research shows that the circulating neutrophil population in humans consists of diverse subtypes and should not be studied as a single ...

the-isolation-characterization-low-normal-density-neutrophils-from

Research

JoVE Journal

Immunology and Infection

Neutrophils are among the first cells to arrive on the site of inflammatory immune response, and their functions and mechanisms have been studied extensively in vitro. We demonstrate a standard density gradient separation method to isolate human neutrophils from whole blood using commercially available separation media.

Neutrophil Isolation Protocol

In this video, we describe the procedure for isolating low-density neutrophils, or LDNs, from the peritoneal lavage fluid of a postoperative human patient. The LDNs thus obtained can be used in further downstream experiments to understand their role in tumor growth and progression.

Peritoneal Low-density Neutrophil Isolation: A Technique to Obtain Low-density Neutrophils from Peritoneal Lavage Fluid Using Magnetic Activated Cell Sorting

In this video, we demonstrate the isolation of cytotoxic high-density neutrophils and low-density neutrophils from the blood of a tumor-bearing mouse by discontinuous sucrose gradient centrifugation.

Isolation of Cytotoxic Neutrophils from Tumor-Bearing Mouse Blood

This video demonstrates an in vitro assay to study neutrophil-biofilm interaction. The pathogenic bacteria embedded in the biofilm and isolated neutrophils were tagged using fluorescent labels, and the immune response by the neutrophils and the evasion of the immune response by the bacteria were assessed using a fluorescence microscope.

An In Vitro Assay to Study the Interaction between Neutrophils and Biofilm

Neutrophils play an important role not only in host defense against invading microorganisms, but are also involved in the immune surveillance of tumor cells. Here, we describe techniques related to the isolation of neutrophils with anti-tumor properties and methods for monitoring anti-tumor neutrophil function in vitro and in vivo.

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Neutrophils are the most abundant type of white blood cells. The isolation of neutrophils from human blood by density gradient separation method and the differentiation of human promyelocytic (HL60) cells along the granulocytic pathway are described here; to test their role on sensitivity of lymphoma cells to anti-lymphoma agents.

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

New protocols are described here to isolate and characterize microparticles derived from human and mouse neutrophils. These protocols utilize ultracentrifugation, flow cytometry, and immunoblotting techniques to analyze microparticle content, and they can be used to study the role of microparticles derived from various cell types in cellular function.

Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies

This protocol describes a highly sensitive and high throughput neutrophil extracellular trap (NET) assay for the semi-automated quantification of ex vivo NET formation by immunofluorescence three-dimensional confocal microscopy. This protocol can be used to evaluate NET formation and degradation after different stimuli and can be used to study potential NET-targeted therapies.

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation

This protocol details a method for the isolation of neutrophils from whole blood, buffy coats, or leukapheresis membranes, achieving good yield, high purity, and minimal cell activation. We utilize gradient purification, red blood cell (RBC) sedimentation, and RBC lysis to obtain a high-quality/purity neutrophil preparation.

Isolation of Human Neutrophils from Whole Blood and Buffy Coats

This research outlines two techniques for isolating abundant neutrophil extracellular traps (NETs) from rat bone marrow. One method combines a commercial neutrophil isolation kit with density gradient centrifugation, while the other employs only density gradient centrifugation. Both approaches yield functional NETs surpassing those from peripheral blood neutrophils.

Unique Approach for Isolating Rat Bone Marrow Neutrophils with Comparable Capacity

Low-density neutrophils (LDN) increase significantly in several diseases. LDN are usually isolated through cell sorting. We present a practical method to obtain pure and viable LDN. After density-gradient centrifugation of peripheral blood, cells are incubated with magnetic microbeads, and then LDN are separated through magnetic columns.

Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils

Learn to isolate low-density and normal-density neutrophils from human blood using density gradient centrifugation and magnetic separation. This protocol achieves high purity for studying neutrophil heterogeneity in health and disease.

The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood

Explore More Videos